Gmsanjivani LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Gmsanjivani LLP Pharmaceutical Export Portfolio Dataset — 6 Products, $405.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Gmsanjivani LLP — Pharmaceutical Exporter Profile (2026) | 6 Products, $405.6K Trade | TransData Nexus

Product Portfolio — Top 6 by Export Value

Gmsanjivani LLP exports 6 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Semaglutide	Advanced Diabetes Medications	$228.1K	45	4.6%	6
2	Valacyclovir	Antivirals	$123.5K	47	0.1%	12
3	Canagliflozin	Advanced Diabetes Medications	$35.9K	29	4.1%	7
4	Pomalidomide	Advanced Oncology	$13.5K	36	0.3%	10
5	Lomustine	Advanced Oncology	$2.8K	3	2.7%	9
6	Repaglinide	Advanced Diabetes Medications	$1.7K	15	0.0%	10

Gmsanjivani LLP exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $405.6K. The top category is Advanced Diabetes Medications (65.5% of portfolio), followed by Antivirals (30.5%), indicating a concentrated portfolio with the top 5 products accounting for 99.6% of total export value.

Gmsanjivani LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Gmsanjivani LLP is a pharmaceutical exporter based in Mumbai, Maharashtra, India. Established on August 10, 2020, the company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAT-2786. The registered office is located at B-410 Western Edge II, Western Express Highway, Borivali East, Mumbai, Maharashtra, 400066. The company is owned by three designated partners: Hitesh Madanlal Jain, Sanjay Sampatraj Parekh, and Bhavesh Prakash Jain. Gmsanjivani LLP specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

2Manufacturing Facilities

As of the latest available information, Gmsanjivani LLP does not own or operate any manufacturing facilities. The company focuses on sourcing finished pharmaceutical formulations from third-party manufacturers to meet its export requirements. This strategy allows Gmsanjivani LLP to offer a diverse product portfolio without the capital investment associated with owning manufacturing plants.

3Key Leadership

The leadership team at Gmsanjivani LLP comprises three designated partners:

Hitesh Madanlal Jain: Appointed on August 10, 2020, he serves as a designated partner, overseeing the company's strategic direction and operations.

Sanjay Sampatraj Parekh: Also appointed on August 10, 2020, he holds the position of designated partner, contributing to the company's management and decision-making processes.

Bhavesh Prakash Jain: Joined as a designated partner on April 1, 2022, he plays a key role in the company's leadership, focusing on business development and strategic initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Gmsanjivani LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Gmsanjivani LLP's export activities are primarily focused on markets in Asia, Africa, and Latin America. The company has established a presence in countries such as Singapore, Taiwan, and Somalia, with significant export volumes reported. For instance, as of February 23, 2026, Gmsanjivani LLP had exported 3,734 shipments to Singapore, 1,458 to Taiwan, and 999 to Somalia. While the company does not publicly disclose specific regulatory filings or approvals in the United States, European Union, United Kingdom, Australia, or Japan, its focus on emerging markets suggests a strategic emphasis on regions with growing pharmaceutical demand.

2Emerging Markets

Gmsanjivani LLP has made significant inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's export data indicates substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting its commitment to expanding its global footprint. By targeting these regions, Gmsanjivani LLP leverages the increasing demand for affordable and quality pharmaceutical products, positioning itself as a key player in these markets.

3Geographic Strategy

Gmsanjivani LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available information, Gmsanjivani LLP does not publicly disclose its FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's export activities are primarily focused on markets in Asia, Africa, and Latin America, with significant shipments reported to countries such as Singapore, Taiwan, and Somalia. While the company does not provide specific details regarding its FDA status, its strategic focus on emerging markets suggests a tailored approach to regulatory compliance based on target regions.

2WHO & EU GMP

Gmsanjivani LLP does not publicly disclose information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export activities are primarily concentrated in emerging markets, with substantial shipments to countries such as Singapore, Taiwan, and Somalia. While specific certifications are not disclosed, Gmsanjivani LLP's focus on these regions indicates a strategic emphasis on meeting the regulatory requirements pertinent to its target markets.

3CDSCO & Indian Regulatory

Gmsanjivani LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Gmsanjivani LLP operates in a competitive landscape characterized by numerous pharmaceutical exporters targeting emerging markets. While specific competitors are not publicly disclosed, the company's export data indicates significant shipments to countries such as Singapore, Taiwan, and Somalia, suggesting competition with other exporters in these regions. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, positions it in direct competition with other exporters offering similar products. To maintain a competitive edge, Gmsanjivani LLP emphasizes quality, reliability, and compliance with regulatory standards pertinent to its target markets.

2Key Differentiators

Gmsanjivani LLP differentiates itself through its strategic focus on emerging markets, particularly in Asia, Africa, and Latin America. The company's export data highlights substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting its commitment to meeting the growing demand for affordable and quality pharmaceutical products in these regions. Additionally, Gmsanjivani LLP's emphasis on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, allows it to offer a comprehensive product portfolio tailored to the needs of its diverse clientele.

Strategic Position

Buyer Due Diligence Brief — Evaluating Gmsanjivani LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Gmsanjivani LLP's supplier assessment focuses on sourcing finished pharmaceutical formulations from third-party manufacturers to meet its export requirements. The company's export data indicates substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting a consistent and reliable supply chain. While specific details regarding supplier relationships are not publicly disclosed, the company's emphasis on quality, compliance, and timely delivery suggests a robust and dependable supplier network.

2Certifications to Verify

Importers considering partnerships with Gmsanjivani LLP should verify the following certifications to ensure compliance with international standards:

FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure adherence to U.S. regulatory requirements.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (GMP) certification to ensure product quality and safety.

Frequently Asked Questions — Gmsanjivani LLP

How many pharmaceutical products does Gmsanjivani LLP export from India?

Gmsanjivani LLP exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Semaglutide ($228.1K), Valacyclovir ($123.5K), Canagliflozin ($35.9K), Pomalidomide ($13.5K), Lomustine ($2.8K). Total export value is $405.6K.

What is Gmsanjivani LLP's total pharmaceutical export value?

Gmsanjivani LLP's total pharmaceutical export value is $405.6K, based on 175 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Gmsanjivani LLP cover?

Gmsanjivani LLP exports across 3 therapeutic categories. The largest are Advanced Diabetes Medications (65.5%, 3 products), Antivirals (30.5%, 1 products), Advanced Oncology (4.0%, 2 products).

Get Full Gmsanjivani LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Gmsanjivani LLP

Gmsanjivani LLP — Export Portfolio & Destination Treemap

Who is Gmsanjivani LLP? — Company Overview & Market Position

What Does Gmsanjivani LLP Export? — Product Portfolio Analysis

Top Products by Export Value

Gmsanjivani LLP Therapeutic Categories — 3 Specializations